FDA Trial Shows Positive Data On Guided Therapeutics LightTouch Cervical Scan
GT said that the study, which is the basis for seeking FDA approval, also indicated that nearly 40% of women without disease could have avoided potentially painful and
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
The study is thought to be the first ever demonstration in humans of targeted siRNA-containing nanoparticle delivery to tumors using systemic administration, delivery of functional siRNAs, and achievement
DuoPlavin/DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). It is a fixed dose combination medicinal product